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Review Contraception for adolescents with lupus
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Abstract
Sexually active adolescents, including young women with lupus, are at high risk for unplanned pregnancy. Unplanned 
pregnancy among teens with lupus is associated with an elevated risk of poor maternal and fetal outcomes. The 
provision of effective contraception is a crucial element of care for a sexually-active young woman with lupus. 
Unfortunately, providers may be hesitant to prescribe contraception to this group due to concerns about increasing 
the risk of lupus complications. This article reviews the risks and benefits of currently-available contraceptives for young 
women with lupus. Providers are encouraged to consider long-term, highly-effective contraception, such as 
implantables and intrauterine devices, for appropriately selected adolescents with lupus.
Introduction
Systemic lupus erythematosus (SLE) is a chronic, multi-
system autoimmune disorder which affects between 40
and 200 per 100,000 people in the United States and
Europe, depending on ethnic background. Between 15-
20% of these cases occur in children and adolescents [1-
3]. The female-to-male ratio of affected patients is
between 5:1 and 10:1[4]. Adolescent girls are therefore
well-represented among patients with SLE. Appropriate
counseling about contraception is an essential part of the
care of any adolescent. Young people with lupus are typi-
cally evaluated more frequently by their pediatric rheu-
matologist than by their primary care provider, and in
many cases the pediatric rheumatologist functions as the
primary physician. Comfort with contraceptive counsel-
ing in general, and knowledge of the options available to
adolescent girls with lupus in particular, are therefore of
vital importance to the pediatric rheumatologist.
In 2000, the pregnancy rate among girls aged 15 to 19 in
the United States was 84.5 per 1000, which represented a
decrease compared to the 1980s and 1990s but still
greatly exceeded rates of teen pregnancy in Canada and
Western Europe. Of these pregnancies, almost 80% were
unintended, and just over half resulted in a live birth [5].
Data from 2005-2007 show a trend toward increasing
teen pregnancy in the United States[6]. Surveys of adoles-
cent behavior show stable rates of sexual activity, but
declining contraception use. These findings are poten-
tially attributable to decreased intensity of national HIV-
prevention efforts and an increasing emphasis on absti-
nence-only sex education curricula which do not provide
contraception information [7]. Most women with SLE
have normal fertility, and sexually active adolescent girls
with lupus are thus at risk for unplanned conception [8].
For women with lupus, pregnancy poses particular risks,
and practitioners must expend extra effort to help these
patients avoid unplanned pregnancy. Risks during preg-
nancy for women with SLE include worsening disease,
obstetric and fetal complications, and adverse effects of
medications on fetal development.
Pregnancy and fetal complications in women with 
SLE
Lupus flares may occur more frequently during preg-
nancy, although this remains controversial[9]. Disease
status pre-conception is the most important factor
impacting risk of flare during pregnancy, underscoring
the need for women with lupus to plan their childbearing
[10]. The assessment of lupus flare in pregnant women is
complicated by several factors. First, no universally
accepted definition of lupus flare exists. Many common
signs of mild-to-moderate lupus flares, especially fatigue
and musculoskeletal complaints, are frequently observed
in normal pregnancy. Pregnancy can be associated with
laboratory changes, including increases in ESR and C3,
and classical complement activation with decreased C4,
which complicate disease assessment[11]. Finally, preec-
lampsia may be difficult to differentiate from lupus
nephritis[12]. Prospective studies of pregnancy in women
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with SLE have yielded conflicting results, but risk of flare
appears elevated during the second trimester, third tri-
mester, and puerperium in at least a subset of
patients[13-15]. In particular, renal and hematologic
flares may be more frequent, while musculoskeletal flares
are decreased[16].
In addition to flares, obstetric complications and poor
fetal outcomes are more common among women with
S LE com pared to healt h y women. A review of women
treated at the Hopkins Lupus Pregnancy Center from
1987 to 1996 found that hypertension, preeclampsia,
hyperglycemia, gestational diabetes, and bladder infec-
tions were more frequent in pregnant women with lupus.
With the exception of bladder infections, all complica-
tions were more frequent in women taking more than 10
mg/day of prednisone. It is unclear whether these effects
are primarily due to underlying active disease requiring
more intensive prednisone therapy, or to prednisone's
known adverse effects on blood glucose levels and blood
pressure. The Hopkins Lupus Pregnancy Center series
also reported a significant increase in preterm birth, most
frequently caused by premature rupture of membranes.
The incidence of intrauterine growth retardation (IUGR)
was also increased, was more marked among African-
American infants than among white infants, and tended
to be more dramatic the longer the gestational period.
Patients with positive antiphospholipid antibodies expe-
rienced frequent pregnancy loss, especially at 20 weeks
gestation or later. Lupus anticoagulant was a much better
predictor of fetal loss than were anticardiolipin antibod-
ies. Neonatal lupus syndrome, an uncommon but serious
complication of lupus pregnancy, is strongly associated
with maternal anti-Ro antibodies and can lead to com-
plete heart block. No infant in this series was affected by
neonatal lupus syndrome, reflecting the rarity of this
entity [16]. A 2008 review of data from the National Inpa-
tient Sample evaluated available information on over
13,000 admissions for lupus childbirth. As in the Hopkins
series, women with SLE were at significantly increased
risk for pregnancy loss, preterm delivery, preeclampsia,
maternal infections, and thrombosis [17].
More recent series of lupus pregnancies have eluci-
dated particular risk factors for adverse maternal and
fetal outcomes. A retrospective review was performed of
58 SLE patients with 90 pregnancies, seen at the Mayo
Clinic between 1976 and August 2007. Active lupus
nephritis (defined as active urinary sediment with >0.5 g/
day of proteinuria, with normal or abnormal serum crea-
tinine) predisposed to fetal loss, premature delivery, and
obstetric complications including hemolysis, elevated
liver enzymes and low platelets (HELLP) syndrome,
hypertension, and preeclampsia, as compared to women
with SLE but without lupus nephritis. Quiescent lupus
nephritis was not associated with any additional preg-
nancy risks compared to women with SLE who had never
experienced nephritis [18].
Even when disease is inactive, adjustments to previous
treatment regimens are likely to be necessary to optimize
pregnancy outcome. Many medications used in the treat-
ment of lupus are known teratogens or abortifacients.
Mycophenolate mofetil is often used for lupus nephritis
therapy, and as a steroid-sparing agent for other manifes-
tations of SLE. In animal studies, mycophenolate mofetil
caused developmental abnormalities. Multiple human
cases of major fetal abnormalities including facial clefts
and ear anomalies have been reported. Mycophenolate is
classed in pregnancy category D (positive evidence of
human fetal risk) [19]. Methotrexate, used to treat cuta-
neous and musculoskeletal involvement and as a steroid-
sparing agent, is a well- known abortifacient which is
often utilized to treat ectopic pregnancy [20]. Methotrex-
ate has also caused severe congenital malformations
including orthopedic, facial, skull, and central nervous
system abnormalities [21]. Cyclophosphamide, an alky-
lating agent used to treat renal and central nervous sys-
tem complications of lupus, is associated with palate,
limb, eye, and skeletal malformations in humans when
used in the first trimester[22,23]. Thalidomide, occasion-
ally prescribed to treat severe cutaneous lupus, is a noto-
rious teratogen causing severe limb deformities[24].
Beyond the pregnancy risks confronted by all women
w i t h  l u p u s ,  a d o l e s c e n t s  w i t h  S L E  f a c e  a d d i t i o n a l  r i s k s
associated with young age of childbearing. Teenage
mothers in general are at increased risk for premature
delivery, low birth weight or small for gestational age
infants, and neonatal mortality, compared to mothers
ages 20-24 years. Pregnant adolescents are more likely
than adult women to be poor, unmarried, to receive inad-
equate prenatal care, and to have low levels of education.
However, two large studies showed that relative risks for
adverse neonatal outcomes persisted even after control-
ling for these socioeconomic and demographic fac-
tors[25,26].
Contraception
Effective contraception is crucial for sexually active ado-
lescents with SLE, given the multiple risks of pregnancy,
and the complex medical management required to opti-
mize outcomes. Frank, open discussion with adolescent
patients with SLE regarding their sexual activity is an
important part of patient care. Rheumatologists must
emphasize the importance of protection from sexually
transmitted infections (STIs) and unplanned pregnancy,
should the patient decide to become sexually active. No
contraceptive method is ideal; all have benefits and draw-
backs. The risk of use of a given contraceptive must be
balanced against the known significant risks of pregnancy
in an adolescent with lupus. The lack of definitive guide-Tesher et al. Pediatric Rheumatology 2010, 8:10
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lines should not impede the provision of effective contra-
ception to this very high-risk group.
Male and female condoms are safe, inexpensive, and,
when used consistently and correctly, prevent both preg-
nancy and transmission of STIs. Unfortunately, consis-
tent condom use is rare among adolescents. Fewer than
4 0 %  o f  s e x u a l l y  a c t i v e  m a l e  a n d  f e m a l e  r e s p o n d e n t s
under age twenty years reported using condoms at last
intercourse[27]. Increased use correlates with patient
beliefs that condoms are popular with peers, easy to
obtain, build relationship trust, and promote partner
responsibility. In addition, high perceived self-efficacy at
obtaining condoms and negotiating for their use
increases condom use[28,29]. Practitioners caring for
sexually active adolescents with SLE may increase the
effectiveness of their counseling by emphasizing the
aforementioned health beliefs, in addition to discussing
STI and pregnancy prevention. Despite all of the above,
the first-year typical-use contraceptive failure rate of con-
doms, about 15%, (21% for the female condom) is unac-
ceptable in a high-risk population. Barrier methods other
than condoms, such as the diaphragm and cervical cap,
do not protect against STIs and have unacceptably high
typical use failure rates (16% to 31%, depending on the
method chosen and parity of the user) [30]. While rheu-
matologists should encourage condom use by sexually-
active patients to protect against STIs, a second contra-
ceptive method should also be recommended for highly
effective pregnancy protection.
Research on safety of non-barrier contraceptive meth-
ods in women with SLE is scarce. Physicians must select a
contraceptive method on a case-by-case basis, with the
active participation of the adolescent patient. Frequently
the best choice is determined by which method the
patient is willing to use consistently. Methods to consider
include combined estrogen and progestin contraceptives
including oral contraceptive pills(OCPs), contraceptive
patches, and vaginal rings; progestin-only methods
including injectables, implants, and progestin-only pills;
and intrauterine devices. Sexually active adolescents
should be referred for gynecological examination as part
of their general health maintenance. However, current
evidence does not support mandatory pelvic examination
prior to prescribing hormonal contraception[31].
Despite the popularity of estrogen-containing com-
bined contraceptives, many practitioners are hesitant to
prescribe these to women with SLE due to concerns that
exogenous estrogens could provoke lupus flares[32]. SLE
most often occurs in post-pubertal women, and as dis-
cussed above, flar es ma y be increased wit h pr egnancy ,
lending credence to the hypothesis that SLE disease activ-
ity can be augmented by estrogens. Various autoimmune
effects of estrogen have been observed in vitro, including
enhanced T-cell resistance to apoptosis, and increased
numbers of pathogenic naïve autoreactive B cells.
Increased estrogen has also caused enhanced autoimmu-
nity in murine models of SLE[33]. However, the clinical
applicability of these findings is uncertain.
Despite the completion of several well-designed stud-
ies, the safety profile of estrogen-containing oral contra-
ceptives in women with lupus is not clear. Sanchez-
Guerrero et al, in a 2005 study, randomly assigned 162
Mexican women with SLE to combined oral contracep-
tives, a progestin-only pill, or a copper IUD. Women with
highly active disease (SLEDAI >30) at baseline or a his-
tory of thrombosis were excluded. Interestingly, women
with positive antiphospholipid antibodies and smokers
(except women over 35 who smoked >15 cigarettes/day)
were included. The investigators found no significant dif-
ferences between groups in incidence of flares or global
disease activity. There were four occurrences of serious
thromboses, two each in the OCPs and progestin-only
groups, all in women with low-titer positive antiphospho-
lipid antibodies[34]. While these data suggest that OCPs
are safe for at least some patients with SLE, this study was
limited by the large number of patients excluded (of 1981
patients screened, 1533 did not meet inclusion criteria),
as well as by the inclusion of only one ethnic group. Also
in 2005, the SELENA-OC study, a multicenter random-
ized, placebo-controlled trial of combined oral contra-
ceptives in 183 women with lupus, showed no significant
difference in disease activity over one year. This study
included patients with inactive or stable disease, and
excluded women with hypertension, those requiring high
(>0.5 mg/kg/day) oral steroids, and those with evidence
of antiphospholipid antibodies (lupus anticoagulant or
high-titer anticardiolipins), among others. Disease flares
and serious complications including thrombosis and
infection were similar between groups[35]. The SELENA-
OC study results are reassuring regarding safety of OCPs
for a subgroup of women with SLE who are normotensive
with mild, stable disease and no known thrombotic risk
factors, but again, relatively few women with SLE meet
these conditions. Studies of exogenous estrogens in
women with severe SLE with major organ involvement
have not been performed.
Oral contraceptives do have significant benefits,
including high effectiveness when used correctly, rela-
tively low cost, and the ability to discontinue use at any
time. Unfortunately among adolescents, poor compliance
poses a significant barrier to effective use of oral contra-
ceptives[36]. Up to 20-30% of adolescents miss at least
one pill per month. Recommendations on combined oral
contraception for women with SLE can likely be extrapo-
lated to non-oral forms of combined hormonal contra-
ception such as the contraceptive patch and the vaginal
ring, although specific studies are lacking. The vaginal
ring (marketed in the United States as the NuvaRing), inTesher et al. Pediatric Rheumatology 2010, 8:10
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particular, offers some advantages. The NuvaRing
releases 15 μg per day of ethinyl estradiol, less than low-
estrogen oral contraceptives, and frees the woman from
the need to remember a daily pill. A large international
survey of NuvaRing users in 2002 showed high continua-
tion and user satisfaction rates, although it did not specif-
ically address adolescents[37].
Unfortunately, estrogen-containing contraceptives
increase the risk of venous thromboembolism, and are
not recommended for patients with lupus anticoagulant,
antiphospholipid antibodies or history of thrombus[38].
Overall, young women with lupus who are responsible,
motivated nonsmokers, with negative antiphospholipid
antibodies, no history of thrombosis, and stable disease
without renal involvement, may be considered for com-
bined contraceptive therapy. To minimize the risk of
thrombotic complications, a low-estrogen formulation
should be selected, and the patient should be warned to
avoid tobacco use. The majority of adolescents with lupus
are likely not good candidates for estrogen-containing
contraception, and alternatives should be explored.
Several non-estrogen-containing hormonal contracep-
tives are available. Studies specifically addressing throm-
botic risk of progestin-only methods, particularly in high
risk populations, are not available. However, considering
the known thrombotic risks of estrogen-containing con-
traception, non-estrogen methods are likely a more pru-
dent choice in patients with other prothrombotic risk
factors. The progestin-only oral contraceptive ("minipill")
must be taken at the same time each day to maximize effi-
cacy, raising concerns about adherence in adolescents.
Menstrual irregularities are frequent, leading to a discon-
tinuation rate above 50% in some studies[39]. In a 1989-
90 survey of 85 Finnish women with SLE who were of
reproductive age, 32 women (38%) had previously used
progestin-only oral contraceptives. Seventy-eight percent
of them, however, had discontinued this method due to
side effects[40].
Depot medroxyprogesterone acetate (DMPA) injec-
tions, another progestin-only method, provide easy to
use, highly-effective contraception. Injections are needed
only every three months, and DMPA is readily available
and inexpensive. However, long-term use is associated
with decreased bone mineral density (BMD)[41]. While
the decrease in BMD may not be clinically significant in
healthy adolescents, it may be of concern for women with
SLE who have an increased risk of osteopenia due to dis-
ease and to use of corticosteroids. Calcium and vitamin D
supplementation is prudent for adolescents with lupus
who utilize DMPA [42,43]. Irregular menses and weight
gain are also frequent with DMPA use, and continuation
among adolescents is poor[44]. Implanon, a single-rod
etonogestrel-releasing implantable contraceptive, is rela-
tively new, and has several attractive features. Implanon
offers highly-effective contraception for up to three years,
is rapidly reversible, and is easily placed and removed. As
with other progestin-only methods, menstrual irregulari-
ties are frequent[45]. Unlike DMPA, Implanon does not
appear to have a detrimental effect on bone density . A
2000 study evaluated BMD over two years of use of
Implanon, compared to women using a non-hormonal
IUD, and found no significant difference[46]. Although
data on continuation of Implanon in adolescents are lack-
ing, this method could be an excellent choice for some
young women with SLE.
Young women with SLE who desire long-term contra-
ception may also consider the intrauterine device (IUD).
IUDs offer many potential advantages to women with
SLE. They are highly effective, long-lasting, and easily
reversible. IUDs are generally underused in the United
States, mainly due to concerns of increased susceptibility
to pelvic inflammatory disease (PID) and subsequent risk
of decreased fertility. However, an increasing body of evi-
dence suggests that these concerns may be exaggerated. A
large World Health Organization survey reported that
among 4031 women in China who had IUDs inserted, no
case of PID occurred in 9197 woman-years of observa-
tion. In Africa, where STDs are more prevalent than in
China, only eight cases of PID occurred during 1292
woman-years of follow-up. The period of increased risk
was limited to the first 20 days post-insertion[47].
Specific studies of IUD safety in women with lupus are
limited. In Julkunen's 1989-90 cross-sectional survey of
women with SLE in Finland, forty-four women reported
current or previous IUD use, and none had experienced a
major infection or bleeding complication[41]. Sanchez-
Guerrero's 2005 study compared progestin-only oral con-
traceptives, combined oral contraceptives, and the cop-
per IUD over a one-year period in 54 women with SLE.
Four women experienced expulsion of the IUD. Five seri-
ous infections occurred in the IUD group, a non-signifi-
cant increase compared to the other groups. The
infection risk attributable to IUDs is difficult to deter-
mine, as two of the infections were meningitis, and the
authors do not specify whether the other serious infec-
tions were of pelvic origin[35]. However, data on IUD
infection risk in other immunosuppressed populations,
specifically HIV-infected women, are encouraging. Rates
of PID in IUD users were not significantly increased, even
among severely immunocompromised women, compared
to HIV-infected women using other contraception or no
contraception [48,49].
The copper IUD frequently increases menstrual blood
loss, sometimes causing anemia. Dysmenorrhea is also
frequent. The possibility of IUD expulsion may be higher
in young, nulliparous women, and patients should be
educated regarding signs of device expulsion [50]. The
levonorgestrel-releasing intrauterine system (LNG-IUS,Tesher et al. Pediatric Rheumatology 2010, 8:10
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marketed in the U.S. as Mirena) may be a better alterna-
tive than the copper IUD for adolescents because of its
potentially reduced risk of PID compared to the copper
IUD and cycle control benefits [51,52]. Amenorrhea fre-
quently occurs with use of the LNG-IUS, and this device
has been successfully used for treatment of menor-
rhagia[53]. Specific studies of thromboembolic risk of
levonorgestrel alone are lacking. However, levonorg-
estrel-containing combined oral contraception appeared
in some studies to have reduced thrombophilic potential
as compared to OCPs containing "third-generation" pro-
gesterones such as desogestrel[54]. Although data on IUD
use in adolescents is limited, available evidence suggests
high continuation rates, comparable to or better than
rates for OCPs[51].
If unprotected sex occurs, due to either contraceptive
nonuse or method failure, emergency contraception (EC)
can reduce the likelihood of unintended pregnancy.
Emergency contraception in the form of oral levonorg-
estrel has recently become available without a prescrip-
tion in the United States, for purchasers age 17 and over.
As discussed in the preceding paragraph, available evi-
dence indicates a low risk of thrombosis for oral
levonorgestrel. Moreover, the 2005 American College of
Obstetrics and Gynecology policy statement on EC
reported that no deaths or serious complications attribut-
able to EC have occurred, and recommended that EC be
made available to all women including those with con-
traindications to OCPs [55].
Conclusions
Clearly, sexually-active adolescents with SLE require
highly-effective contraception with minimal adverse
effects, which can represent a clinical challenge. Research
specifically addressing contraceptive issues in women
with SLE is limited. However, considering the risks to the
adolescent patient with SLE of an unplanned pregnancy,
providers must not be deterred from providing effective
contraception. Although condom use is important and
should be encouraged, it is not adequate to prevent preg-
nancy in this high-risk population. A combined oral con-
traceptive may be appropriate for a subset of adolescents
with good adherence, mild-to-moderate disease activity,
and no evidence of hypercoagulability. The progesterone-
only minipill is unlikely to worsen lupus activity or pro-
mote thrombosis, but has high discontinuation rates.
DMPA, which offers the advantage of greater typical-use
efficacy than progesterone-only pills, is a reasonable
choice for many adolescents. However, menstrual irregu-
larities are frequent. DMPA's detrimental effects on bone
density are also of concern. The etonogestrel-releasing
implant appears to be a good choice for progesterone-
only long-term contraception, although specific studies
in women with lupus are lacking. Existing evidence does
not support the opinion that a diagnosis of lupus, or
immunocompromise, are contraindications to the use of
an IUD. The copper IUD offers a non-hormonal alterna-
tive for long-term contraception. However, menorrhagia
is frequent among users of copper IUDs, and as anemia is
common in adolescents with SLE, the LNG-IUS may be a
better choice. Adolescents and young women with lupus
who choose to use an IUD should be educated about the
slightly increased risk of upper genital tract infection in
the first month after insertion, and should also be
instructed on self-exams to check for unrecognized IUD
expulsions. Education regarding the safety and availabil-
ity of emergency contraception, and provision of an EC
prescription to fill in case of need, are also appropriate in
many circumstances. Regardless of the method chosen,
active participation by pediatric rheumatologists in con-
traceptive counseling for adolescents with lupus is a criti-
cal part of these patients' care.
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